Last reviewed · How we verify
Kanamycin B (BEKANAMYCIN)
Kanamycin B (generic name: BEKANAMYCIN) is a bekanamycin drug. It is currently in Phase 3 development.
Bekanamycin works by disrupting the bacterial cell membrane, ultimately leading to cell death.
Kanamycin B, also known as Bekanamycin, is a small molecule antibiotic of the bekanamycin class. Its mechanism of action is not well-documented, but it is believed to target bacterial cell membranes. Bekanamycin is not FDA-approved for any indications, and its commercial status is unclear. Further research is needed to determine its efficacy and safety profile. As a result, it is not widely used in clinical practice.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BEKANAMYCIN |
|---|---|
| Drug class | bekanamycin |
| Target | 3-oxoacyl-[acyl-carrier-protein] synthase 3 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Imagine the bacterial cell membrane as a protective shield. Bekanamycin inserts itself into this shield, causing it to become unstable and eventually leading to the cell's demise. This process ultimately results in the death of the bacterial cell, effectively treating the infection.
Approved indications
Common side effects
Key clinical trials
- Relative Efficacy of Loteprednol (Lotemax®) vs. Loteprednol/Tobramycin (Zylet®) in Treatment of Chronic Ocular Surface Inflammation Associated With Meibomian Gland Dysfunction (MGD)/Posterior Blephari (Phase 4)
- Bioequivalence and Safety Study of Vantobra and TOBI Nebulizer Solutions in Healthy Subjects (Phase 1)
- Drug Elution Profile and Minimum Inhibitory Concentration of Antibiotic-loaded Cement After Primary Total Knee Arthroplasty (Phase 3)
- Amikacin Pharmacokinetics to Optimize Dosing Recommendations and Patho(Physiological) Considerations in Neonates With Perinatal Asphyxia Treated With Hypothermia (NA)
- Management of Ventilation Acquired Pneumonia Caused by Pseudomonas and Acinetobacter Organisms in a Pediatric Center: a Randomized Controlled Study (Phase 3)
- A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medications (One a Prostaglandin) Treated With Two Trabecular Micro-bypass Stents (iStent Inject) and a Postoperativ (Phase 4)
- STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB (Phase 3)
- A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment o (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kanamycin B CI brief — competitive landscape report
- Kanamycin B updates RSS · CI watch RSS
Frequently asked questions about Kanamycin B
What is Kanamycin B?
How does Kanamycin B work?
What is the generic name of Kanamycin B?
What drug class is Kanamycin B in?
What development phase is Kanamycin B in?
What does Kanamycin B target?
Related
- Drug class: All bekanamycin drugs
- Target: All drugs targeting 3-oxoacyl-[acyl-carrier-protein] synthase 3
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing